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Abstract
The emergence of artemisinin (ART) resistance in Plasmodium falciparum intra-erythrocytic
parasites has led to increasing treatment failure rates with first-line ART-based combination
therapies in Southeast Asia. Decreased parasite susceptibility is caused by K13 mutations,
which are associated clinically with delayed parasite clearance in patients and in vitro with
an enhanced ability of ring-stage parasites to survive brief exposure to the active ART
metabolite dihydroartemisinin. Herein, we describe a panel of K13-specific monoclonal anti-
bodies and gene-edited parasite lines co-expressing epitope-tagged versions of K13 in
trans. By applying an analytical quantitative imaging pipeline, we localize K13 to the parasite
endoplasmic reticulum, Rab-positive vesicles, and sites adjacent to cytostomes. These lat-
ter structures form at the parasite plasma membrane and traffic hemoglobin to the digestive
vacuole wherein artemisinin-activating heme moieties are released. We also provide evi-
dence of K13 partially localizing near the parasite mitochondria upon treatment with dihy-
droartemisinin. Immunoprecipitation data generated with K13-specific monoclonal
antibodies identify multiple putative K13-associated proteins, including endoplasmic reticu-
lum-resident molecules, mitochondrial proteins, and Rab GTPases, in both K13 mutant and
wild-type isogenic lines. We also find that mutant K13-mediated resistance is reversed upon
co-expression of wild-type or mutant K13. These data help define the biological properties
of K13 and its role in mediating P. falciparum resistance to ART treatment.
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Author summary
The development of drug resistance in Plasmodium falciparum parasites presents a signifi-
cant impediment to the global fight against malaria. Partial resistance to artemisinin
(ART), the core component of current first-line drugs, has swept across Southeast Asia. In
P. falciparum-infected patients, ART-resistant parasites show slow rates of clearance fol-
lowing treatment with an ART derivative or ART-based combination therapy. Resistance
to partner drugs has also emerged in Southeast Asia, leading to frequent treatment fail-
ures. Single amino acid mutations in the P. falciparum K13 protein constitute the primary
genetic cause of ART resistance and predict an increased risk of treatment failure. By gen-
erating monoclonal antibodies, we have investigated the subcellular localization of K13 in
dihydroartemisinin-treated or untreated parasites. Analytical microscopy data localize
K13 to or near the endoplasmic reticulum and vesicles that mediate intracellular traffick-
ing, including plasma membrane-associated cytostomes that import host hemoglobin into
the parasite. Co-immunoprecipitation experiments with K13-specific monoclonal anti-
bodies identified multiple proteins associated with the endoplasmic reticulum, vesicular
trafficking, the cytosol, or the mitochondria, with no apparent differences between K13
mutant and wild-type parasites. We also observed that overexpression of mutant or wild-
type K13 in K13 mutant parasites could restore susceptibility, supporting the hypothesis
that K13 mutations cause loss of function.
Introduction
Worldwide, malaria results in an estimated 400,000 or more fatalities each year, afflicting
mostly infants and young children in sub-Saharan Africa [1]. Treatment of asexual blood-
stage infections caused by Plasmodium falciparum, the most virulent human malaria parasite,
relies on the efficacy of artemisinin (ART)-based combination therapies (ACTs). These first-
line treatments pair a derivative of ART, an exceptionally fast-acting and potent antimalarial,
with a longer-lived partner drug [2]. Commonly used partners include the arylaminoalcohol
lumefantrine, used primarily in Africa, and piperaquine, a bisquinoline used predominantly in
Southeast Asia [3].
In parasites, activation of ART or its derivatives requires iron-mediated reductive scission
of the compound’s central endoperoxide bridge. The activator is thought to be primarily Fe2+
heme, a byproduct of parasite-mediated catabolism of host hemoglobin [4]. This cleavage
event generates carbon-centered free radicals that can target proteins, lipids, nucleic acids, and
heme itself, resulting in rapid cellular damage and parasite death [5–8]. ART is characterized
by its ability to eliminate parasites from all stages of the intra-erythrocytic developmental cycle
(IDC), including the young ring stages that form shortly after parasites invade host red blood
cells (RBCs) [9,10]. This drug is highly potent against trophozoites that undergo maximal
endocytosis and degradation of host hemoglobin, thus providing an abundant source of free
heme.
Emerging resistance to ACTs threatens to reverse recent progress in reducing the global
burden of malaria. Having first appeared in western Cambodia over a decade ago, resistance to
ART is now nearly at fixation across Southeast Asia [11–15]. Clinically, ART resistance is
defined as delayed parasite clearance after artesunate monotherapy or treatment with an ACT.
As resistance to ART has become more widespread, selection pressure on partner drugs has
increased. In some cases, delayed parasite clearance has escalated to treatment failure as
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partner drugs have succumbed to resistance [16]. In northeastern Thailand, a recent report
documented 87% treatment failure rates with dihydroartemisinin (DHA) plus piperaquine
[15].
In vitro, ART resistance is restricted to early ring-stage parasites, and is quantified as
increased survival in the ring-stage survival assay (RSA0-3h), wherein parasites are exposed to a
brief pulse (700 nM for 6h) of DHA. This assay distinguishes resistant parasites, which exhibit
�1% survival after three days, from sensitive parasites that do not survive the pulse [17]. This
resistance phenotype does not extend to the later trophozoite stage, presumably because para-
sites cannot counter the substantial toxicity arising from ART-mediated alkylation of the
abundant heme moieties generated at this stage.
ART resistance is attributed primarily to individual point mutations in the parasite Kelch
protein K13 [18]. Select mutations in K13 associate with delayed parasite clearance in P. falcip-
arum-infected patients and with elevated survival in the RSA0-3h [18,19]. These mutations all
map to the protein’s carboxy-terminal six-bladed beta-propeller domain, a characteristic com-
ponent of Kelch proteins that often serves as a scaffold for protein-protein interactions.
Among the mutations examined in vitro, R539T and I543T confer the highest levels of ART
resistance [20]. In contrast, the C580Y mutation confers only a modest degree of resistance,
yet is the most prevalent in Southeast Asia [20,21]. This finding has been attributed to the rela-
tively minimal fitness cost conferred by the C580Y mutation in Southeast Asian parasites [22].
In addition to its propeller domain, K13 comprises an apicomplexan-specific domain of
unknown function and a BTB/POZ dimerization domain. The latter is found in a subset of
Kelch proteins that commonly mediate ubiquitin-dependent protein degradation via the pro-
teasome by serving as substrate adaptors for E3 ubiquitin ligases [18,23]. K13 shows homology
with the mammalian BTB-Kelch protein Keap1, which controls the cell’s adaptive response to
oxidative stress [18,24]. In P. falciparum, the K13 gene appears to be essential based on condi-
tional knockout experiments showing that K13-deficient parasites do not progress past the
ring stage and transition into non-viable condensed forms, and by a large-scale saturation
mutagenesis study that observed no disruptions in the K13 coding region [25,26].
Mechanistic studies have led to several proposals for how mutant K13 might counter ART-
mediated cellular toxicity. These proposals include lowering the levels of the heme activator of
ART including via reduced hemoglobin endocytosis in rings [27–30], upregulating endoplas-
mic reticulum (ER) stress-response pathways [31], reducing the levels of ubiquitinated pro-
teins [32], promoting translational arrest via differential phosphorylation of the translation
initiation factor eIF2α [33], or increasing levels of the phospholipid phosphatidylinositol-3-
phosphate (PI3P) [34,35]. To gain additional insight into the biology of this protein, we raised
K13-specific monoclonal antibodies (mAbs) and used these to interrogate this protein’s sub-
cellular localization in DHA-exposed or vehicle-treated asexual blood-stage parasites. Using
co-immunoprecipitation (co-IP), we also identified potential interactions with other parasite
proteins and examined their predicted roles in P. falciparum metabolism and development.
Results presented herein implicate K13 in multiple cellular functions, including vesicular traf-
ficking and ER homeostasis, and suggest an unexpected association with the mitochondria
upon DHA treatment.
Results
K13 localizes to the endoplasmic reticulum and to vesicular structures
To probe the subcellular localization of K13, we raised monoclonal antibodies (mAbs) by
immunizing mice with recombinant protein fragments consisting of either the K13 propeller
domain alone or the propeller domain plus the upstream BTB/POZ domain, and cloning
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K13-specific hybridoma populations. Western blot screening identified the E9 clone that rec-
ognized the two recombinant K13 immunogens (bands at ~25 kDa and ~35kDa for the propel-
ler domain alone or propeller plus BTB/POZ domains, respectively) (Fig 1A). In parallel, we
generated recombinant NF54WTattB parasite lines that express endogenous wild-type (WT)
K13 and co-express stably-integrated transgenic copies of WT or C580Y K13, which were N-
terminally tagged with GFP or 3HA, respectively. These lines are referred to herein as
NF54WTattB-GFP-K13WT or NF54WTattB-3HA-K13C580Y (Table 1 and S1A–S1C Fig).
We tested our E9 mAb by Western blot against asynchronous parasite extracts from the
contemporary Cambodian isolate Cam3.II that carries the K13 R539T mutation (referred to
herein as Cam3.IIR539T) and its isogenic, gene-edited K13 WT counterpart Cam3.IIWT [20].
This K13 mAb clearly labeled WT and mutant K13 (both at ~85 kDa), with evidence of
reduced K13 labeling in Cam3.IIR539T parasites (Fig 1A and S1D Fig). Quantification provided
evidence of a slight reduction in K13 protein levels in the Cam3.IIC580Y and Cam3.IIR539T syn-
chronized ring-stage parasites (these decreases were estimated at ~24% and ~34%, respec-
tively) compared to WT levels (S1E Fig). We also tested the GFP- or HA-tagged NF54WTattB
lines expressing K13 in trans, revealing bands at ~110 kDa for GFP-K13WT and ~86 kDa for
3HA-K13C580Y (Fig 1A and S1D Fig) that were also recognized by anti-GFP- or anti-HA anti-
bodies respectively.
Our K13-specific E9 mAb was found to be suitable only for Western blots and to not pro-
vide a robust signal by immunofluorescence assay (IFA). Further screening led us to identify a
second K13-specific mAb, clone E3, which was suitable for IFAs (but not Western blots). This
mAb was tested against the parasite lines NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y. These assays allowed us to calculate the overlap coefficient (termed the Pear-
son correlation coefficient, PCC) between the signal from our K13 E3 mAb and that from
anti-GFP or anti-HA antibodies tested against epitope-tagged K13 proteins. PCC values range
from +1 (indicating complete overlap) to 0 (random association) to -1 (mutually exclusive sig-
nals with zero overlap). In both the GFP and HA tagged lines we observed a very high degree
of correlation between the signals from the anti-K13 mAb E3 and anti-GFP or anti-HA anti-
bodies, with PCC values of 0.96 and 0.83, respectively (Fig 1B). These Western blot and IFA
results with native and epitope or fluorescent protein-tagged lines validated the specificity of
our K13-specific mAbs.
Using our E3 mAb, we next examined the subcellular localization of K13 throughout the
IDC by IFA. These assays were performed on tightly synchronized parasites and used the
Cam3.IIWT and Cam3.IIR539T isogenic lines. Samples were collected every 12h beginning with
early rings (0-3h post invasion (hpi)). Early rings showed a single K13-positive focus within
the parasite cytosol in both lines. As parasites progressed into schizonts, the number of
K13-positive foci increased. Whereas the majority of these foci appeared to be evenly distrib-
uted throughout the parasite cytosol, others appeared to be proximal to specific organelles
including the parasite plasma membrane, the ER, and the digestive vacuole (DV). No differ-
ences in K13 localization were evident between WT and mutant parasites (Fig 1C). Super-res-
olution microscopy clearly showed multiple K13 foci in trophozoites of both K13 mutant and
WT parasites (Fig 1D; S2A and S2B Fig). Three-dimensional rotations suggested elongated,
tunnel-like shapes that might link subcellular compartments (S1 Video). Quantification of the
number of visualized K13 foci estimated a 48% reduction in Cam3.IIR539T trophozoites com-
pared with Cam3.IIWT trophozoites (S2C Fig).
We also examined K13 localization using immunoelectron microscopy (IEM; Fig 1D).
These studies were conducted with NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y parasites, with K13 detected via anti-GFP or anti-HA colloidal gold-conjugated
primary antibodies. In trophozoites, K13 appeared to localize to the parasite cytosol, often
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within small vesicles, vesicular clusters, or tubulovesicular networks that likely belong to the
ER or the Golgi apparatus. K13 was also frequently associated with the ER itself, as well as with
the plasma and nuclear membranes and the DV. We also saw evidence of K13 associating with
cytostomes that traffic host-endocytosed hemoglobin from the parasitophorous vacuolar space
to the DV (Fig 1E).
K13 overexpression restores artemisinin sensitivity to K13-mutant
parasites
Our epitope-tagged lines made it possible to further explore the relationship between co-
expression of mutant or WT K13 in trans and endogenous mutated or wild-type K13. The
impact of co-expression on in vitro resistance was measured using the RSA0-3h. As sensitive
and resistant benchmarks, NF54WT and NF54C580Y parasites (expressing K13 WT or C580Y
respectively) yielded mean RSA survival values of 1.0% and 4.8% respectively (Fig 1F). Co-
Fig 1. The P. falciparum artemisinin resistance determinant K13 localizes to the parasite ER and intracellular vesicles. (A) Western blots
probed with the E9 monoclonal antibody (mAb) raised against the K13 propeller domain. Left to right: recombinant K13 protein fragments
used as immunogens; Cam3.IIWT and Cam3.IIR539T asexual blood-stage parasite extracts; and NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y extracts. ERD2 was used as a loading control for the Cam3.II lines. The NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y blots were also probed with anti-GFP or anti-HA antibodies, respectively. (B) Immunofluorescence assay (IFA) images
showing K13 localization in NF54WTattB-GFP-K13WT (top) and NF54WTattB-3HA-K13C580Y (bottom) trophozoites. Parasites were co-
stained with the K13 E3 mAb and antibodies specific to GFP or HA. Pearson correlation coefficient (PCC) values indicate the degree of spatial
co-localization between the two signals and were calculated by determining the fluorescence intensity correlations of Alexa Fluor 488 (anti-
GFP or anti-HA) and 594 (K13 mAb). Nuclei were stained with DAPI (blue). Scale bars: 2 μm. (C) IFA images depicting K13 localization in
Cam3.IIWT (top) and Cam3.IIR539T (bottom) parasites throughout asexual blood-stage development. Parasites were stained with the K13 E3
mAb. Sampling was performed every 12h, beginning with tightly synchronized 0–3 hpi ring-stage parasites. Scale bars: 2 μm. (D) Super
resolution microscopy of mature parasites labeled with antibodies to K13 (green), the cytosolic marker HAD1 (red) and the nuclear stain
DAPI (blue), showing K13-positive punctate foci. Scale bars: 2 μm. A video representation is shown in S1 Video. (E) Representative
immunoelectron microscopy (IEM) images depicting K13 localization in NF54WTattB-GFP-K13WT or NF54WTattB-3HA-K13C580Y parasites
stained with 18 nm colloidal gold-conjugated anti-GFP or anti-HA antibodies. Arrowheads highlight locations of interest. ER, endoplasmic
reticulum; Hz, hemozoin; N, nucleus; PVM, parasitophorous vacuolar membrane. Scale bars: 100 nm. (F) Ring-stage survival assay (RSA0-3h)
results from NF54WTattB-GFP-K13WT, NF54C580YattB-GFP-K13C580Y, NF54WTattB-3HA-K13WT and NF54WTattB-3HA-K13C580Y transgenic
lines, compared to the sensitive and resistant benchmarks NF54WT and NF54C580Y, respectively. Data show mean ± SEM percent survival of
700 nM dihydroartemisinin (DHA)-treated early ring-stage parasites (0–3 hpi) compared with control dimethyl sulfoxide (DMSO)-treated
parasites processed in parallel. Experiments were performed on 2–6 independent occasions with technical duplicates.
https://doi.org/10.1371/journal.ppat.1008482.g001
Table 1. Plasmodium falciparum lines employed in this study.
Name Strain Endogenous K13 locus Transgene Transgene 5’ UTR
NF54WT NF54 WT – –
NF54C580Y NF54 C580Y – –
NF54WTattB-GFP-K13WT NF54attB WT GFP-K13WT (integrated into cg6 attB) K13
NF54C580YattB-GFP-K13C580Y NF54attB C580Y GFP-K13C580Y (integrated into cg6 attB) K13
NF54WTattB-3HA-K13WT NF54attB WT 3HA-K13WT (integrated into cg6 attB) pbef1α
NF54WTattB-3HA-K13C580Y NF54attB WT 3HA-K13C580Y (integrated into cg6 attB) pbef1α
Cam3.IIR539T Cam3.II R539T – –
Cam3.IIWT Cam3.II WT – –
Cam3.IIC580Y Cam3.II C580Y –
CamWT CamWT WT – –
CamWTC580Y CamWT C580Y – –
Dd2WT GFP-Rab6 Dd2 WT Rab6-GFP (episome) pfsec12
Dd2R539T GFP-Rab6 Dd2 R539T Rab6-GFP (episome) pfsec12
Dd2WT Sec24A-GFP Dd2 WT Sec24A-GFP (episome) pfsyntaxin17
3D7WT Mito-hGrx1-roGFP2 3D7 WT Mito-hGrx1-roGFP2 pfcrt
https://doi.org/10.1371/journal.ppat.1008482.t001
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expression of GFP-K13WT or 3HA-K13C580Y in our NF54WTattB epitope-tagged lines (see
above) led to ART sensitivity, with RSA values of 0.8% and 0.7% in the NF54WTattB-GFP-
K13WT and NF54WTattB-3HA-K13C580Y lines, respectively. As comparators, we also engi-
neered an NF54C580YattB line co-expressing GFP-K13C580Y as well as an NF54WTattB line
co-expressing 3HA-K13WT (Table 1). The former line expresses mutant K13 in both the
endogenous and transgene loci and demonstrated a nominally less sensitive phenotype (with
1.6% mean RSA survival), relative to the fully sensitive NF54WT line. The latter line expresses
WT K13 in both loci and was fully sensitive (mean RSA survival 1.0%). These data confirm
that mutant K13 does not confer resistance in a dominant-negative manner and suggest that
overexpression of the mutant protein mostly reverts K13 mutant parasites to DHA sensitivity.
Our results agree with recently published evidence that the RSA0-3h phenotype inversely corre-
lates with K13 abundance and that K13 levels are reduced in mutant parasites relative to WT
[27,28].
K13 co-immunoprecipitates with vesicular transport, ER, and
mitochondrial proteins
To identify putative K13-interacting partners, we performed six independent HPLC/MS-MS-
based co-IP experiments using two K13 mAbs (E3 and D9, which both yielded robust IFA sig-
nals). These experiments comprised 13 test samples from parasite cultures enriched in 0–12
hpi rings. These samples were prepared from Cam3.II lines expressing WT, C580Y or R539T
K13, as well as from CamWT lines expressing WT or C580Y K13 (Table 1 and S1 Table). For
a given sample, we retained only proteins that were identified by�3 peptide spectra. We then
filtered results across all samples by retaining only proteins that were present in�3 of the 6
independent experiments and�5 of the 13 test samples, and absent in all of the 10 negative
control samples (i.e. that used an unrelated antibody, or used affinity columns without the
addition of anti-K13 antibodies). Results showed that K13 was by far the most abundant pro-
tein detected, representing 22% of the total number of spectra detected in our filtered list of 83
high-confidence immunoprecipitated proteins (Table 2). In a secondary analysis, we relaxed
the criteria to allow for proteins that appeared in 1 to 3 negative control samples (out of 10),
while retaining the positive criteria listed above. This yielded an additional 90 proteins as puta-
tive interactors (S2 Table).
After K13, the most abundant protein in our co-IPs was S-adenosylmethionine (SAM) syn-
thetase (also known as methionine adenosyltransferase), a redox-regulated enzyme that pro-
duces the methyl donor S-adenosylmethionine used in methylation reactions of multiple
substrates including nucleic acids, proteins, phospholipids and amines [36]. Adenosylhomo-
cysteinase (also known as adenosylhomocysteine hydrolase), another enzyme involved in the
methionine metabolism pathway that produces SAM, was also in the top six most abundant
proteins. Phosphoglycerate mutase 1 (PGM1) was the second most abundant protein, with
phosphoglucomutase 2 (PGM2) being less abundant. Intriguingly PGM5, the mammalian
homolog of PGM2, tethers the K13 ortholog Keap1 to the mitochondria [37,38]). PGM1 is
annotated as being involved in parasite glycolysis, a pathway implicated with several other
immunoprecipitated proteins. The receptor for activated c kinase (RACK), a cytosolic multi-
functional scaffolding protein, was also abundant.
Consistent with our data that localized K13 to intracellular foci, we reproducibly co-immu-
noprecipitated K13 with several proteins involved in vesicular trafficking (Table 2 and S2
Table). These included multiple members of the Rab family of GTPases, namely Rab1A,
Rab1B, Rab5C, Rab6, Rab7, Rab11B, and Rab18B, which function as regulators of vesicular
trafficking and endocytosis in eukaryotes [39]. By applying an overrepresentation test in the
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Table 2. Putative K13-interacting protein partners identified by co-immunoprecipitation and LC/MS-MS.
PlasmoDB
Gene ID










(of 13 total, 6
WT, 7 mutant)2
PF3D7_1343700 Kelch protein K13 K13 Putative CUL3 ubiquitin ligase
adaptor protein
22.19% 6 13 (6,7)
PF3D7_0922200 S-adenosylmethionine synthetase SAMS Methionine metabolism 5.19% 3 6 (3,3)
PF3D7_1120100 Phosphoglycerate mutase 1, putative PGM1 Glycolysis 3.58% 4 8 (4,4)
PF3D7_0826700 Receptor for activated c kinase RACK Cytosolic multi-functional
scaffolding protein
2.47% 5 9 (3,6)




ALG2 CUL3 ubiquitin ligase adaptor
protein, with role in dolichol
metabolism
2.32% 6 11 (5,6)
PF3D7_0520900 Adenosylhomocysteinase SAHH Methionine metabolism 2.15% 3 6 (3,3)
PF3D7_1026800 40S ribosomal protein S2 RPS2 Small ribosomal subunit 1.76% 6 12 (5,7)
PF3D7_1444800 Fructose-bisphosphate aldolase FBPA Glycolysis 1.72% 3 6 (3,3)
PF3D7_0105200 RAP domain-containing protein – Altered transcription following
inhibition of polyamine and
methionine metabolism enzymes
1.51% 5 12 (5,7)
PF3D7_0915400 ATP-dependent
6-phosphofructokinase
PFK9 Cytoplasm 1.50% 3 5 (2,3)
PF3D7_0822600 Protein transport protein Sec23 SEC23 COPII mediated vesicular
transport
1.50% 4 7 (3,4)
PF3D7_0934500 V-type proton ATPase subunit E,
putative
– Ca2+ homeostasis 1.49% 5 11 (5,6)
PF3D7_0626800 Pyruvate kinase PyrK Glycolysis / Interaction with
HDAC1
1.49% 4 6 (3,3)
PF3D7_1008700 Tubulin beta chain – Microtubules 1.40% 4 8 (4,4)
PF3D7_1412500 Actin II ACT2 Actin filaments 1.38% 4 9 (4,5)
PF3D7_0929200 RNA-binding protein, putative – RNA-binding protein 1.27% 3 6 (2,4)
PF3D7_0927300 Fumarate hydratase, putative FH Mitochondrial TCA cycle 1.24% 6 9 (4,5)
PF3D7_0623500 Superoxide dismutase [Fe] SOD2 Mitochondrial antioxidant system 1.21% 4 8 (4,4)
PF3D7_0820700 2-oxoglutarate dehydrogenase E1
component
KDH Mitochondrial TCA cycle 1.20% 3 7 (3,4)
PF3D7_1037100 Pyruvate kinase 2 PyKII Apicoplast / Isoprenoid
metobolismmetabolism
1.19% 4 8 (4,4)
PF3D7_0608800 Ornithine aminotransferase OAT Ornithine metabolism 1.18% 3 5 (2,3)
PF3D7_1302100 Gamete antigen 27/25 Pfs27/25 Early marker of gametocyte
development
1.13% 4 8 (3,5)
PF3D7_1327800 Ribose-phosphate
pyrophosphokinase, putative
– Pentose phosphate cycle 1.12% 5 7 (2,5)
PF3D7_0823900 Dicarboxylate/tricarboxylate carrier DTC Mitochondrial antioxidant system,
TCA cycle
1.07% 4 9 (4,5)
PF3D7_1215000 Thioredoxin peroxidase 2 Trx-Px2 Mitochondrial antioxidant system 1.06% 4 7 (2,5)
PF3D7_1472600 Protein disulfide-isomerase PDI-14 Oxidative protein folding in the
ER, component of chaperone
complexes that interact with BiP
1.06% 4 7 (3,4)
PF3D7_0720400 Ferrodoxin NADP+ reductase – Mitochondrial iron-sulfur protein
biogenesis
1.05% 3 5 (2,3)
PF3D7_1468700 Eukaryotic initiation factor 4A eIF4A Eukaryotic translation initiation
factor 4F complex
1.02% 4 7 (3,4)
(Continued)
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(of 13 total, 6
WT, 7 mutant)2
PF3D7_0722200 Rhoptry-associated leucine zipper-
like protein 1
RALP1 Rhoptry neck protein 0.99% 4 6 (4,2)
PF3D7_1410600 Eukaryotic translation initiation
factor 2 subunit gamma, putative
eIF2g Eukaryotic translation initiation
factor 2 complex
0.92% 3 7 (3,4)
PF3D7_1338200 60S ribosomal protein L6-2, putative – Large ribosomal subunit 0.92% 4 9 (4,5)
PF3D7_1320000 Golgi protein 1 GP1 ER-Golgi translocation and quality
control
0.89% 3 6 (3,3)
PF3D7_1437700 Succinyl-CoA ligase, putative – Mitochondrial TCA cycle 0.86% 4 6 (1,5)
PF3D7_0829200 Prohibitin, putative PHB1 Mitochondrial protein
degradation
0.83% 4 9 (4,5)
PF3D7_0621200 Pyridoxine biosynthesis protein
PDX1
PDX1 Vitamin B6 synthesis 0.83% 3 6 (3,3)
PF3D7_1330600 Elongation factor Tu, putative – Mitochondrial protein translation 0.83% 4 8 (3,5)
PF3D7_0616800 Malate:quinone oxidoreductase,
putative
MQO Mitochondrial TCA cycle, ETC 0.81% 4 7 (2,5)
PF3D7_0624000 Hexokinase HK Glycolysis 0.79% 3 6 (3,3)
PF3D7_0920800 Inosine-5’-monophosphate
dehydrogenase
IMPDH Purine metabolism 0.78% 3 5 (2,3)
PF3D7_0511800 Inositol-3-phosphate synthase INO1 Inositol phosphate metabolism 0.73% 3 5 (3,2)
PF3D7_0727200 Cysteine desulfurase, putative NFS Mitochondrial iron-sulfur protein
biogenesis
0.72% 3 5 (1,4)
PF3D7_0813900 40S ribosomal protein S16, putative – Ribosome 0.70% 3 9 (3,6)
PF3D7_1108400 Casein kinase 2, alpha subunit CK2a Cytoplasm, nucleus, calcium
dependent protein kinase (CK2
complex)
0.69% 4 9 (4,5)
PF3D7_1115600 Peptidyl-prolyl cis-trans isomerase CYP19B Oxidative protein folding in the
ER, component of chaperone
complexes that interact with BiP





– Mitochondrial TCA cycle 0.68% 4 7 (3,4)
PF3D7_1408600 40S ribosomal protein S8e, putative – Ribosome 0.68% 3 6 (2,4)
PF3D7_0816600 Chaperone protein ClpB ClpB Chaperone-assisted protein
folding (apicoplast and/or
mitochondrion)
0.68% 4 8 (3,5)
PF3D7_1133400 Apical membrane antigen 1 AMA1 Invasion molecule 0.67% 3 6 (2,4)
PF3D7_0709700 Prodrug activation and resistance
esterase
PARE Cytosolic esterase, putative lipase 0.65% 5 9 (4,5)
PF3D7_0401800 Plasmodium exported protein
(PHISTb), unknown function
PfD80 Maurer’s cleft exported protein 0.64% 4 8 (4,4)
PF3D7_0316800 40S ribosomal protein S15A, putative – Ribosome 0.63% 5 9 (5,4)
PF3D7_1465900 40S ribosomal protein S3 – Ribosome 0.62% 3 6 (2,4)
PF3D7_0106800 Ras-related protein Rab5C RAB5C Intracellular traffic / Endocytosis 0.61% 3 6 (3,3)
PF3D7_1025300 Conserved Plasmodium protein,
unknown function
– No known or predicted function 0.60% 3 6 (2,4)
PF3D7_1136300 Tudor staphylococcal nuclease TSN mRNA splicing 0.60% 4 7 (2,5)
PF3D7_1361100 Protein transport protein Sec24A SEC24A COPII mediated vesicular
transport
0.59% 4 6 (2,4)
(Continued)
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PANTHER classification system for biological processes, we observed an 18-fold enrichment
in Rab proteins, with a p value of 1×10−6 (S3 Table; http://pantherdb.org; [40,41]). K13-spe-
cific mAbs also co-immunoprecipitated Sar1, which assists in COPII coat assembly, and Sec23














(of 13 total, 6
WT, 7 mutant)2
PF3D7_1439400 Cytochrome bc1 complex subunit
Rieske, putative
– Mitochondrial cytochrome bc1
complex (ETC)
0.55% 4 7 (3,4)
PF3D7_1452000 Rhoptry neck protein 2 RON2 Invasion molecule 0.54% 3 5 (2,3)
PF3D7_1212500 Glycerol-3-phosphate 1-O-
acyltransferase
GAT ER membrane protein /
Glycerolipid synthesis
0.54% 4 8 (3,5)
PF3D7_0922500 Phosphoglycerate kinase PGK Glycolysis 0.50% 4 5 (2,3)
PF3D7_1008400 26S proteasome AAA-ATPase
subunit RPT2, putative
RPT2 Proteasome 0.49% 4 6 (3,3)
PF3D7_0416800 Small GTP-binding protein Sar1 SAR1 COPII mediated vesicular
transport
0.49% 4 7 (4,3)
PF3D7_0810600 ATP-dependent RNA helicase DBP1,
putative
DBP1 Helicase 0.48% 3 6 (2,4)
PF3D7_1145400 Dynamin-like protein DYN1 Clathrin-mediated vesicular
transport
0.45% 3 6 (3,3)
PF3D7_0309600 60S acidic ribosomal protein P2 PfP2 Ribosome 0.43% 4 5 (3,2)
PF3D7_0112200 Multidrug resistance-associated
protein 1
MRP1 Plasma membrane component /
glutathione and redox metabolism
0.41% 3 6 (3,3)
PF3D7_0504600 2-oxoisovalerate dehydrogenase
subunit beta, mitochondrial, putative
BCKDHB Mitochondrial TCA cycle 0.41% 3 6 (3,3)
PF3D7_1306400 26S proteasome AAA-ATPase
subunit RPT4, putative
RPT4 Proteasome 0.36% 3 5 (2,3)
PF3D7_0524000 Karyopherin beta KASb Import and export through the
nuclear pore
0.35% 4 6 (3,3)
PF3D7_0702500 Plasmodium exported protein,
unknown function
– Maurer’s cleft exported protein 0.33% 3 7 (3,4)
PF3D7_1361900 Proliferating cell nuclear antigen 1 PCNA1 DNA replication and repair 0.32% 3 6 (2,4)
PF3D7_0507100 60S ribosomal protein L4 RPL4 Ribosome 0.30% 3 6 (3,3)
PF3D7_1247400 Peptidyl-prolyl cis-trans isomerase
FKBP35
FKBP35 Cytoplasm, nucleus, centrosome 0.30% 3 5 (1,4)
PF3D7_0213700 Conserved Plasmodium protein,
unknown function
– No known or predicted function 0.30% 3 5 (3,2)
PF3D7_0217900 Conserved Plasmodium protein,
unknown function
– Putative thioesterase 0.29% 3 5 (1,4)
PF3D7_0205900 26S proteasome regulatory subunit
RPN1, putative
RPN1 Proteasome 0.29% 3 5 (3,2)
PF3D7_0719700 40S ribosomal protein S10, putative – Ribosome 0.28% 3 5 (1,4)
PF3D7_1105000 Histone H4 H4 Nucleus 0.27% 4 5 (3,2)
PF3D7_0413500 Phosphoglucomutase 2, putative PGM2 Glycolysis 0.25% 3 6 (3,3)
PF3D7_0520000 40S ribosomal protein S9, putative – Ribosome 0.23% 3 7 (4,3)
PF3D7_1129200 26S proteasome regulatory subunit
RPN7, putative
RPN7 Proteasome 0.22% 3 5 (3,2)
1A summary of these experiments can be found in S2 Table.
2The 13 samples were derived from Cam3.IIWT (4), Cam3.IIR539T (4), Cam3.IIC580Y (2), CamWTWT (2), and CamWTC580Y (1).
https://doi.org/10.1371/journal.ppat.1008482.t002
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transport vesicles budding from the ER. In P. falciparum, Sec24a has been localized to transi-
tional ER sites where it mediates the capture of COPII vesicle cargo [42]. Our co-IP studies
also identified other ER-associated proteins, including Sec61, part of the ER-Sec61 translocon
complex [43,44], the luminal protein disulfide isomerase (PDI-14), and two peptidyl-prolyl
cis-trans isomerases (CYP19B and FKBP35) that catalyze protein folding in the ER.
Multiple members of the eukaryotic translation machinery were also identified, including pro-
tein components of the 40S and 60S ribosomes and several translation initiation or elongation fac-
tors (EIF1α, eEF2, eIF2α, eIF4A), as well as several nucleic acid-binding proteins (including SR1
and SR4). Multiple components of the 19S regulatory particle of the 26S proteasome were
observed, notably RPT2, RPT4, RPN1, and RPN7. The 26S proteasome likely has a role in degrad-
ing ART-damaged proteins, supporting a potential role for K13 as a ubiquitin ligase adaptor pro-
tein that could help deliver polyubiquinated proteins for proteasome-mediated degradation [45].
We also identified several proteins that localize to the DV, wherein host hemoglobin is
degraded leading to the release of reactive heme. These include the hemoglobin-processing
enzyme plasmepsin II, and the membrane proteins PfCRT and falcilysin, with the latter also
being involved in transit peptide degradation in the apicoplast and mitochondria [46].
Unexpectedly, several proteins were also detected that are known or predicted to localize to
mitochondria. These include the Rieske protein that is part of the cytochrome bc1 complex, as
well as prohibitin 1 that is implicated in mitochondrial morphogenesis and that is a possible regu-
lator of mitochondrial membrane potential [47]. Components of the TCA cycle (including fuma-
rate hydratase, the 2-oxoglutarate dehydrogenase E1 component, a dicarboxylate/tricarboxylate
carrier, succinyl-CoA ligase, malate:quinone oxidoreductase, and the 2-oxoisovalerate dehydroge-
nase beta subunit) were also observed. We also identified factors thought to be involved in mito-
chondrial translation (elongation factor Tu), protein degradation (the ATP-dependent protease
subunit ClpQ, the ATP-dependent zinc metalloprotease FTSH 1, and the mitochondrial-process-
ing peptidase alpha subunit), iron-sulfur protein biogenesis (ferrodoxin NADP+ reductase and
cysteine desulfurase), as well as two putative mitochondrial chaperones (HPS40 and CPN20).
Other potential K13-interacting proteins associated with the mitochondria included the
ATP synthase F1 alpha subunit (involved in mitochondrial energy metabolism), mitochondrial
matrix protein 33, and a putative dynamin (involved in mitochondrial fission). Finally, several
proteins were associated with the mitochondrial antioxidant system, including superoxide dis-
mutase, thioredoxin peroxidase 2, isocitrate dehydrogenase, the succinyl-CoA synthetase
alpha subunit, a lipoamide acyltransferase, and the glutathione peroxidase-like thioredoxin
peroxidase. PANTHER overrepresentation analysis focusing on cellular components revealed
a 15-fold enrichment in mitochondrial proteins, with a p value of 4×10−4 (S4 Table).
In reviewing putative functional features of proteins in our K13 co-IP list (Table 2 and S2
Table), we observed an apparent enrichment of proteins known to undergo post-translational
modifications, specifically palmitoylation (73 proteins), glutathionylation (59 proteins), and S-
nitrosylation (53 proteins). In comparison, 409, 493 and 319 proteins with these respective
modifications were identified from the total asexual blood stage proteome (comprising over
4,800 proteins based on detected expression ([48–51]; http://mpmp.huji.ac.il)). This corre-
sponds to an estimated three to five-fold enrichment in these proteins among putative
K13-interacting partners.
K13 partially co-localizes with proteins involved in vesicular trafficking
and cytostomes
To further interrogate the putative interactors identified by our co-IP studies, we performed
quantitative co-localization studies using our K13 mAbs or K13 tagged lines combined with
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other epitope-tagged lines or primary antibodies to proteins of interest. Initial experiments
focused on the Rab GTPase family and the Sec23/24 heterodimer. For these studies, we pre-
pared highly synchronized early ring-stage parasites (0–3 hpi) and pulsed these for 6h with 700
nM DHA. Control cultures were mock-treated with DMSO vehicle. Parasites were harvested
at various time points post drug pulse and subsequently fixed and stained for microscopic
analysis (S3 Fig). To increase throughput and reproducibility we developed a quantitative
analysis pipeline in collaboration with Nikon software engineers for image processing and
determination of PCC values (listed in S5 Table).
We first assayed the Cam3.IIWT and Cam3.IIR539T lines with antibodies to Rab5A, 5B, or
5C, along with our K13-specific E3 mAb. Samples were collected immediately post drug treat-
ment (0h time point, ~6 hpi), and, in the case of Rab5A, also at 12h post pulse (~18 hpi). IFAs
with anti-K13 and anti-Rab5A antibodies showed an intermediate degree of spatial association
between the two proteins immediately (0h) post pulse in Cam3.IIWT and Cam3.IIR539T, with
median PCC values for both lines centering around 0.5 (Fig 2A and S4A Fig). At this time
point, we observed no effect of DHA treatment on PCC values in either line. At 12h post pulse,
however, we observed a statistically significant increase in PCC values for both mutant and
WT parasites in DHA-treated cultures as compared to mock (DMSO) treatment (Fig 2B and
S4B Fig). At this 12h time point with DHA-treated parasites, the PCC values for K13 and
Rab5A were significantly higher for K13 WT parasites compared with their mutant counter-
parts (median 0.65 vs 0.43; p<0.001; Fig 2B and S5 Table).
The putative K13 associations with Rab5B or Rab5C were also examined immediately post
DHA or DMSO treatment. Median PCC values for K13 and Rab5B or Rab5C were slightly
lower than for Rab5A in both Cam3.IIWT and Cam3.IIR539T parasites (Fig 2C and 2D and S4A
Fig). For both Rab5B and 5C, a slightly stronger association with K13 was observed in WT par-
asites compared with the mutants, a trend that became statistically significant upon DHA
treatment (p<0.05 and p<0.01, respectively). With all three Rab proteins, there was a trend
towards slightly lower PCC values immediately post DHA treatment (0h time point) in the
K13 mutant line and slightly increased PCC values in the K13 WT line. These data suggest
decreased levels of endocytosis in K13 mutant parasites following DHA exposure.
We subsequently assessed the spatial association between K13 and Rab6, a trans-Golgi
marker known to direct exocytic vesicles to the plasma membrane in mammalian cells [52].
These experiments were conducted using Dd2 K13 WT or R539T parasites expressing
Rab6-GFP episomally. PCC values were moderately high in both DMSO-treated lines, and
were significantly increased in both lines directly post DHA pulse, with the highest levels of
association (median 0.73) observed in DHA-treated K13 WT parasites (Fig 2E, S4C Fig and
S5 Table).
We continued our IFA analyses with the late endosome marker Rab7 and the post Golgi
marker Rab11A, using the Cam3.IIWT and Cam3.IIR539T lines and antibodies to K13 and the
two Rab proteins. For Rab7 we observed relatively high median PCC values, centering around
0.6, regardless of K13 allele status. These remained unchanged immediately post DHA treat-
ment (0h time point; Fig 2F and S4D Fig). For Rab11A we measured high PCC values for co-
localization with K13 in Cam3.IIR539T parasites for all time points and conditions examined,
including 0h and 12h post DHA and DMSO treatments (median 0.70–0.84; Fig 2G and 2H,
S4D and S4E Fig, and S5 Table). In contrast, median PCC values for K13 and Rab11A were
significantly lower in WT parasites than in mutant parasites at both time points, in particular
for DMSO-treated cultures (0.60–0.61; S5 Table). A slight but nonetheless significant increase
was observed in K13 and Rab11A association in WT parasites immediately after DHA treat-
ment (0h time point; p<0.01), bringing PCC values to the level of K13 mutant parasites, but
these values dropped again at 12h post treatment (Fig 2G and 2H).
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To extend these co-localization studies, we also performed ultrastructural analyses via IEM.
These studies used the NF54WTattB-GFP-K13WT and NF54WTattB-3HA-K13C580Y lines, which
were stained with anti-GFP or anti-HA colloidal gold-conjugated primary antibodies. Co-
staining with antibodies specific for Rab proteins localized K13 (black arrowheads) to sites
Fig 2. K13 partially co-localizes with vesicular transport proteins and sites adjacent to cytostomes. (A-H) PCC values quantifying the degree of spatial co-
localization between K13 and (A, B) Rab5A, (C) Rab5B, (D) Rab5C, (E) Rab6, (F) Rab7, and (G, H) Rab11A, with accompanying representative 3D volume
reconstructions of IFA images. Assays were conducted using Cam3.IIR539T or Cam3.IIWT parasites, except in the case of Rab6, where Dd2R539T or Dd2WT parasite lines
expressing GFP-Rab6 were employed. Samples were collected either directly following a 6h 700 nM pulse of DHA (A, C-G; denoted 0h) or 12h post pulse (B, H). DMSO
was used as a vehicle control. K13 was labeled using the E3 mAb (green). Rab proteins were labeled with specific antibodies (red) or, in the case of Rab6, anti-GFP
(green, with K13 this time in red). PCC values were calculated from the fluorescence intensity correlations of Alexa Fluor 488 and either Alexa Fluor 594 or Alexa Fluor
647. For PCC plots, each dot represents an individual parasitized RBC. Horizontal lines represent the median with interquartile range. Two-tailed unpaired t tests were
used to calculate p values. �p<0.05; ��p<0.01; ���p<0.001; ����p<0.0001. Scale bars: 1 μm. (I) IEM images of trophozoite-stage NF54WTattB-GFP-K13WT (left) or
NF54WTattB-3HA-K13C580Y (right) parasites co-stained with anti-GFP or anti-HA, respectively, and anti-Rab5A (two upper panels), anti-Rab7 (bottom left) or anti-
Rab5B plus anti-PDI (bottom right). Secondary antibodies were conjugated to colloidal gold particles of different sizes. Arrowheads highlight locations of interest. ER,
endoplasmic reticulum; N, nucleus. Scale bars: 100 nm. (J) IEM images of NF54WTattB-GFP-K13WT (left) or NF54WTattB-3HA-K13C580Y (right) trophozoites stained
with anti-GFP or anti-HA, respectively. Arrowheads highlight locations of interest. Hz, hemozoin; N, nucleus; PM, plasma membrane. Scale bars: 100 nm unless
otherwise indicated.
https://doi.org/10.1371/journal.ppat.1008482.g002
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either within or adjacent to vesicles containing Rab5A, Rab5B or Rab7 (white arrowheads; Fig
2I and S4F Fig). In some IEM images we also observed K13 near cytostomes (Fig 2J).
Our co-IP data suggested that K13 might also partially associate with the transitional ER
marker Sec24a, involved in vesicle budding from the ER. To examine this further, we tested
our anti-K13 E3 mAb on a Sec24a-GFP expressing parasite line that harbors WT K13 [42].
Quantitative IFA analyses revealed intermediate to high median PCC values (0.60–0.67) for
Sec24a and K13, with no significant changes upon DHA treatment (S4G and S4H Fig).
K13 partially co-localizes with the ER chaperone BiP but not with the cis-
Golgi marker ERD2
Given that K13 also co-immunoprecipitated a number of ER-associated proteins (Table 2 and
S2 Table), we performed imaging analyses using markers for the ER and cis-Golgi, namely
BiP and ERD2, respectively. To test for K13 and BiP spatial association, we applied high-reso-
lution 3D structured illumination microscopy to ring- and schizont-stage parasites. These
assays employed the Cam3.II K13 WT and R539T mutant lines, which were stained with anti-
K13 and anti-BiP antibodies (Fig 3A). In the ring stages, both mutant and WT K13 proteins
localized to foci associated with the BiP-labeled ER, whereas in the schizont stages only R539T
K13 showed evidence of a close spatial association with BiP. This association was supported
via widefield immunofluorescence microscopy with trophozoites (S5A Fig). Close proximity
between K13 and the ER was also observed by IEM studies with NF54WTattB-GFP-K13WT par-
asites labeled with anti-BiP and anti-GFP antibodies (S5B Fig), as well as our previous IEM
studies with triple labeling of K13, Rab5B and the ER chaperone PDI (white arrowheads; Fig
2I and S4F Fig).
We next assessed the degree of co-localization between K13 and BiP in DMSO- and DHA-
treated Cam3.IIWT or Cam3.IIR539T samples throughout the first half of the IDC, with time
points taken at 0h, 3h, 12h and 24h post treatment (S3 Fig). In DMSO-treated samples we
observed a non-significant trend towards lower PCC values in K13 WT samples as compared
to mutant samples across all time points tested (Fig 3B–3E and S5C Fig). At the 0h time point,
for example, PCC values for K13 and BiP averaged 0.72 and 0.64 for Cam3.IIR539T and Cam3.
IIWT respectively (S5 Table). By comparison, a very recent study using K13-specfic polyclonal
antiserum reported a PCC value of 0.58 between WT K13 and BiP [53]. Interestingly, following
DHA treatment, mutant and WT parasites showed significant differences at 12h post drug
pulse (Fig 3E and S5C Fig). Whereas PCC values for WT parasites dropped significantly post
DHA treatment, PCC values for K13 and BiP in R539T parasites were highest post DHA treat-
ment at this time point (median 0.82; S5 Table).
In light of the proximity between the cis-Golgi and sites of vesicle budding from the ER, we
compared association coefficients obtained with BiP to those measured using ERD2, a marker
of the cis-Golgi, using the same lines. In contrast to the high PCC values observed for K13 and
BiP in Cam3.IIWT or Cam3.IIR539T, for K13 and ERD2 we measured moderate to low PCC val-
ues regardless of the condition and parasite line tested (median 0.39–0.4; Fig 3F and 3G, S5D
Fig and S5 Table). These data argue against K13 being present in the cis-Golgi.
To assess whether K13 localization was affected by blocking ER-to-Golgi transport, we
exposed parasites to the fungal metabolite brefeldin A (BFA). This agent perturbs secretory
traffic in parasites, resulting in retention of secreted proteins within the ER [54]. In these
experiments, we treated Cam3.II K13 WT and mutant ring-stage parasites (0–3 hpi) with BFA
or vehicle control (EtOH) for 1h before harvesting and co-staining with anti-K13 and antibod-
ies to either BiP or ERD2. After the BFA pulse we observed a significantly higher association
between K13 and BiP in K13 mutant parasites, as compared with the ethanol (EtOH) mock-
PLOS PATHOGENS P. falciparum K13 properties and artemisinin Resistance
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008482 April 20, 2020 14 / 35
PLOS PATHOGENS P. falciparum K13 properties and artemisinin Resistance
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008482 April 20, 2020 15 / 35
treated population (median 0.85 vs 0.64, respectively; S5 Table). By comparison, we measured
significantly lower PCC values for K13 and BiP in BFA-pulsed vs mock-treated K13 WT para-
sites (median 0.68 vs 0.56; Fig 3F and S5 Table). In contrast, PCC values for K13 and ERD2
remained moderate regardless of the treatment (BFA or mock; Fig 3J) and were equivalent to
those observed in the DHA and DMSO treatments in both lines (Fig 3F). The increased associ-
ation between BiP and mutant K13 upon BFA treatment was further illustrated for Cam3.
IIR539T in 3D volume reconstructions of K13- and BiP-labeled ring-stage parasites (Fig 3I).
K13 shows an elevated association with mitochondria post
dihydroartemisinin pulse
To explore the link between K13 and the mitochondrial proteins observed in our co-IP studies
(Table 2 and S2 Table), we quantified the degree of co-localization between K13 and mito-
chondria using our anti-K13 antibodies together with the live mitochondrial dye MitoTracker
Deep Red. PCC values were determined either immediately (0h) or 12h post drug pulse (i.e. 6h
of DHA or DMSO vehicle). These assays used the NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y lines, as well as the isogenic Cam3.II K13 WT and R539T pair. Median PCC
values for mock-treated parasites were low (ranging from -0.03 to 0.25), as shown in represen-
tative images (Fig 4A–4E and S6 Table). After DHA treatment we observed significantly
increased associations between the mitochondria and K13 at both time points in all parasite
lines tested, particularly at the 12h time point in NF54WTattB-GFP-K13WT parasites (median
PCC value 0.84 in DHA-treated parasites vs. 0.44 in mock-treated; S6A Fig and S6 Table). For
the isogenic Cam3.IIR539T and Cam3.IIWT lines, a greater increase was observed in the mutant
parasites as compared to their K13 WT counterparts, especially 12h post drug treatment (Fig
4D). The increased co-localization observed between parasite mitochondria and K13 following
DHA treatment was not detected when MitoTracker-labeled parasites were co-stained with
Rab5A, Rabb11A, TRiC or ERD2 (S6B–S6E Fig).
IEM studies of NF54WTattB-3HA-K13C580Y parasites stained with colloidal gold-labeled
anti-HA antibodies revealed some K13 labeling within parasite mitochondria (Fig 4F).
Because mitochondria associate with the ER at specialized membrane contact sites [55], we
also investigated whether K13 might be present near these signaling hubs (Fig 4G and S6F
Fig). For these studies, untreated Cam3.IIR539T or Cam3.IIWT trophozoites were incubated
with MitoTracker prior to formaldehyde fixation and co-staining with anti-BiP and anti-K13
antibodies. Interestingly, we frequently observed an overlap of all three labels in both mutant
and WT K13 parasites, as indicated in the white dotted outlines (Fig 4G and S6F Fig).
Fig 3. K13 shows substantial co-localization with the ER chaperone BiP but not with the cis-Golgi marker ERD2.
(A) 3D SIM microscopy images showing Cam3.IIR539T or Cam3.IIWT parasites co-stained with the K13 E3 mAb
(green) and antibodies to the ER chaperone BiP (red). SIM: structured illumination microscopy. Scale bars: 1 μm. (B,
C) PCC values quantifying co-localization between K13 and BiP at 0h post DHA (6h, 700 nM) pulse, alongside
representative IFA images. DMSO was used as a vehicle control. Assays were conducted using the Cam3.IIR539T and
Cam3.IIWT lines. Parasites were co-stained with the K13 E3 mAb and antibodies to BiP. PCC values were calculated
and statistics performed as in Fig 2. Scale bars: 2 μm. (D, E) PCC values for co-localization of K13 and BiP at (D) 3h or
(E) 12h post drug pulse. Assays were conducted and PCC values were calculated as in (B). (F, G) PCC values
quantifying co-localization between K13 and ERD2 at 0h post DHA pulse, alongside representative IFA images.
Parasites were co-stained with the K13 E3 mAb and antibodies to ERD2. Assays were otherwise conducted as in (B).
Scale bars: 2 μm. (H-J) PCC values for co-localization of K13 and BiP or ERD2 following a 1h treatment with Brefeldin
A (BFA; 5 μg/ml). EtOH was used as a vehicle control. Assays were conducted using the Cam3.IIR539T and Cam3.IIWT
lines. (I) 3D volume reconstruction of deconvolved Z-stacks (15 image stacks, step size of 0.2 μm) of Cam3.IIR539T
ring-stage parasites treated with BFA and co-stained with anti-K13 mAb E3 and anti-BiP (top) or anti-ERD2 (bottom).
Scale bars: 1 μm.
https://doi.org/10.1371/journal.ppat.1008482.g003
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Fig 4. K13 shows an increased association with the mitochondria post DHA pulse. (A) PCC values for the association of K13 with parasite mitochondria in NF54
WTattB-GFP-K13WT or NF54WTattB-3HA-K13C580Y ring-stage parasites co-stained with MitoTracker Deep Red and anti-GFP antibodies. Samples were collected
directly post DHA pulse (6h, 700 nM). DMSO was used as a vehicle control. (B) Representative fluorescence microscopy images and 3D reconstructions of NF54WT-
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We next examined whether atovaquone (ATQ), an inhibitor of the Plasmodium mitochon-
drial cytochrome bc1 complex, might affect K13 co-localization with the mitochondria. These
studies assayed Cam3.IIR539T and Cam3.IIWT rings treated for 4h with 60 nM DHA and/or
ATQ tested at 100 nM or 1,200 nM concentrations. 60 nM DHA produced no change in PCC
values for K13 and MitoTracker compared to DMSO (Fig 4H and 4I). 100 nM or 1,200 nM
ATQ also generated no change in PCC values between Cam3.IIR539T and Cam3.IIWT parasites.
In contrast, PCC values increased significantly in Cam3.IIR539T parasites exposed to a combi-
nation of 60 nM DHA and 100 or 1,200 nM ATQ (Fig 4H and 4I). This result was observed to
a lesser extent in Cam3.IIWT parasites but only at the higher ATQ concentration. Elevated
ring-stage survival was observed for Cam3.IIR539T but not Cam3.IIWT parasites following a 6h
exposure to 60 nM DHA ± 100 nM ATQ (S6G Fig).
DHA leads to an oxidizing effect in the mitochondria
To further investigate a possible role for parasite mitochondria in the response to DHA, poten-
tially as sensors of DHA-induced oxidative stress, we tested whether DHA treatment results in
mitochondrial oxidation. For these experiments, we used the ratiometric redox-sensor
hGrx1-roGFP2, consisting of human glutaredoxin 1 fused to an oxidation-reduction sensitive
GFP and an N-terminal leader sequence that targets this reporter protein to parasite mito-
chondria. Assays used P. falciparum 3D7 parasites episomally transfected with pARL1a-Mito-
hGrx1-roGFP2 (referred to herein as 3D7WT Mito-hGrx1-roGFP2) [56] for confocal live-cell
imaging. For these studies, we tested DHA, ATQ, and the β-hematin binding drug chloroquine
(CQ). Results were compared to mock-treated control parasites. DIA and DTT were included
as separate treatments to achieve complete oxidation and reduction, respectively. Results
showed that young trophozoites exposed to DHA for 4h underwent a very high degree of mito-
chondrial oxidation, more than twice the levels observed with ATQ or CQ with similar expo-
sure times and drug concentrations. Increased mitochondrial oxidation with DHA was also
observed after 24h. Mitochondrial oxidation was not observed after 30 minutes of parasite
exposure to DHA, ATQ or CQ (Fig 4J).
Discussion
With the rise of ART-resistant P. falciparum parasites in Southeast Asia [11,12], the identifica-
tion of K13 as the molecular marker of ART resistance represented a key breakthrough in
tracking their spread and examining the underlying biological basis of resistance [18]. Here,
we have explored the biological role of K13 in DHA- and vehicle-treated asexual blood stage
parasites with the use of K13-specific mAbs and recombinant lines expressing epitope-tagged
attB-GFP-K13WT (left) or NF54WTattB-3HA-K13C580Y (right) ring-stage parasites treated and stained as in (A). Scale bars: 1 μm unless otherwise indicated. (C, D) PCC
values for the association of K13 with the mitochondria in Cam3.IIR539T or Cam3.IIWT ring-stage parasites co-stained with MitoTracker and the K13 mAb E3. Samples
were collected either (C) immediately post DHA pulse (6h, 700 nM) or DMSO mock treatment or (D) 12h post pulse. (E) Representative fluorescence microscopy
images and 3D reconstructions of Cam3.IIR539T ring-stage parasites 12h post DHA pulse or DMSO mock treatment. Scale bars: 1 μm. (F) Representative IEM images of
NF54WTattB-3HA-K13C580Y trophozoites treated with DHA (9 nM for 3h) or a DMSO vehicle control and stained with anti-HA antibodies to detect K13. Arrowhead
highlights location of interest. M, mitochondria; N, nucleus. Scale bar: 100 nm. (G) 3D volume reconstruction of untreated late Cam3.IIR539T and Cam3.IIWT
trophozoites triply stained with MitoTracker, anti-BIP (ER, green) and anti-K13 E3 (purple). White dotted outlines indicate spatial overlap between the three labels.
Scale bars: 1 μm. (H, I) PCC values for the association of K13 with mitochondria in (H) Cam3.IIR539T or (I) Cam3.IIWT ring-stage parasites treated for 4h with 60 nM
DHA, or 100 nM or 1200 nM ATQ, or combinations thereof. Samples were co-stained with MitoTracker and the K13 mAb E3. (J) Percent mitochondrial oxidation
(OxD; see Methods) measured in the 3D7WT Mito-hGrx1-roGFP2 reporter line. Parasites were treated with DHA, ATQ, CQ, a known oxidizing agent (DIA), a known
reducing agent (DTT), or vehicle control (denoted CTL). Parasites were exposed for 30 min to 100 μM drug concentrations, for 4h to 5 μM drug, or for 24h to 50 nM
drug. Experiments were performed on three independent occasions, with 10 parasites per experiment examined using confocal laser scanning microscopy. Results are
presented as means ± SEM. Significance was calculated using two-tailed, unpaired t tests comparing drug-treated with mock-treated parasites. �p<0.05; ��p<0.01;
���p<0.001; ����p<0.0001. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; DIA, diamide; DTT, 1,4-dithiothreitol.
https://doi.org/10.1371/journal.ppat.1008482.g004
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WT or mutant K13. These tools were used in immunofluorescence and IEM-based co-localiza-
tion studies, and in co-IP experiments to identify putative K13-associated proteins. Our find-
ings suggest an association between K13 and the ER, as well as a role for K13 in vesicular
trafficking processes, including cytostomes that transport endocytosed host hemoglobin. We
also provide evidence of an association between K13 and mitochondrial proteins and their res-
ident organelle post DHA treatment.
Our IFA results localized K13 to punctate foci that increase in number throughout the para-
site IDC. K13 appears to segregate with daughter merozoites, suggesting that the protein is
ready to function within very young ring-stage parasites. This observation is consistent with
K13-mediated ART resistance occurring in early rings, despite the peak of K13 protein expres-
sion occurring in mid trophozoites [17,31,57,58]. Using IEM, we partially co-localized K13 to
vesicles in close proximity to the perinuclear ER, the DV and the plasma membrane. We also
obtained evidence of K13 localizing near cytostomes, sites where the plasma membrane invagi-
nates to deliver endocytosed hemoglobin to the parasite DV. These results extend prior obser-
vations of K13 associating with the ER or vesicular structures as well as sites of cytostomal
formation, as defined using GFP-tagged endogenous K13 or polyclonal K13-specific antibod-
ies [25,27,28,35]. Evidence of K13 localizing to cytostomes was also obtained recently using
correlative light and electron microscopy [27], a highly-specialized technique that was unavail-
able for our study. K13 localization patterns were consistent between isogenic WT and mutant
Cam3.II lines, as assessed using both K13-specific mAbs and our 3HA- or GFP-tagged
NF54WTattB lines, indicating that K13 mutations did not affect subcellular localization.
Of note, the NF54WTattB-3HA-K13C580Y line, which expresses an integrated mutant K13
allele expressed in trans, did not show elevated RSA0-3h survival, suggesting that the endoge-
nous WT isoform is dominant and that K13 polymorphisms might be loss-of-function muta-
tions. RSA data also showed that gene-edited NF54C580YattB-GFP-K13C580Y parasites
harboring an integrated second K13 C580Y allele (that results in resistance) reverted to a
nearly sensitive phenotype (Fig 1F). These findings are consistent with data recently published
using episomally transformed K13 mutant parasites [27].
We also observed less labeling of K13 R539T relative to the WT form both by Western blot
and by microscopic quantification of K13-positive foci (S1E and S2C Figs), consistent with
quantitative proteomic analyses showing a ~2-fold decrease in K13 protein abundance in
Cam3.IIR539T rings as compared to isogenic WT rings [59]. These data suggest that the R539T
mutation in this Cam3.II background might reduce K13 protein levels and that this might con-
stitute one causal aspect of mutant K13-mediated ART resistance. Increased overall expression
of mutant K13 via co-expression of the endogenous protein and second mutant copy in trans
thus presumably ablates resistance by compensating for a loss of function in the endogenous
locus (Fig 1F). In broad agreement with these results, a recent study using K13 conditional
knock-sideways parasites showed that mislocalization of K13 can lead to resistance [28]. Fur-
ther studies will be required to assess whether K13 mutations can differ in their impact on pro-
tein stability and activity, how this varies between strains, and to what extent these effects
correlate with ART resistance.
Our co-IP experiments resulted in an array of putative K13-associated proteins (Table 2
and S2 Table), suggesting that K13 may interact with multiple proteins across several core
pathways including vesicular trafficking, redox regulation and unexpectedly, mitochondrial
metabolism and physiology, as discussed below. Our results suggested that few if any interac-
tions were specific to either the WT or mutant K13 isoforms. Many of our candidate K13-asso-
ciated proteins were also observed in a recent study that used GFP-Trap beads to affinity
purify GFP-K13 followed by LC/MS-MS [53]. These proteins included S-adenosylmethionine
synthetase (the most abundant protein in our dataset), elongation factor 2, and plasmepsin II.
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Our list, however, is distinct from the proteins identified in the recent study by Birnbaum et al.
[27] that used a quantitative dimerization-induced bio-ID approach (DiQ-BioID) in which
GFP-tagged K13 forms a complex with RFP-tagged biotin ligase using dimerization domains
regulated by the addition of rapalog. That system enabled biotinylation of K13-proximal pro-
teins, which were then affinity-purified on a streptavidin Sepharose column prior to mass
spectrometry and protein identification. One of the proteins identified using this approach,
Eps15, was also shown to identify K13 in a reciprocal DiQ-BioID experiment. These proteins
were localized to a clathrin-independent AP-2 adaptor complex-labeled compartment
involved in hemoglobin endocytosis. Of note, K13 colocalized with AP-2μ, although this pro-
tein was not identified by affinity purification of K13 in either the Birnbaum study or our own.
A separate study also did not identify K13 upon affinity purification of HA-tagged AP-2μ pro-
tein [60]. We cannot yet explain the discrepancy between the data we obtained by co-IP with
our K13 mAb and that generated using the DiQ-BioID method, although we note that DiQ-
BioID will preferentially identify proteins in the same compartment as K13 rather than pro-
teins physically bound to K13. Our list may have preferentially identified the latter. We also
note differences in the protein detergent-based extraction protocols. Further work is clearly
required to resolve these differences.
Our list of potential interacting partners for K13, based on co-IP and co-localization data,
includes multiple Rab GTPases (Fig 5). These included Rabs associated in other eukaryotes
with early (Rab5A, 5B, 5C), late (Rab7) or recycling endosomes (Rab 11A, 11B) or the trans-
Golgi (Rab6). These and other observed Rabs (e.g. 1A, 1B and 18B) help regulate intracellular
cargo trafficking via their association with effector proteins [61,62]. In the case of Rab11A, the
consistently high PCC co-localization values with K13 in Cam3.IIR539T parasites (Fig 5) sug-
gest the possibility of increased export and recycling functions in mutant parasites, which may
help eliminate damaged and aggregated proteins during the post-drug recovery phase.
DHA treatment differentially impacted certain correlation values obtained for K13 WT and
mutant parasites, as evidenced with Rab5A, B and C. For these, we observed significantly
higher PCC values for K13 WT parasites post DHA treatment as compared with K13 R539T
mutant parasites. Rab5 proteins have been implicated in hemoglobin import processes, sug-
gesting that the differential associations might impact hemoglobin uptake [63–66]. These find-
ings recall the recent report of reduced heme and heme-DHA adducts in K13 mutant parasites
[29,30]. Birnbaum et al. also recently showed reduced endocytosis of host cytoplasm, which
consists mainly of hemoglobin, in ring-stage parasites expressing mutant K13 (compared to an
isogenic WT control) or WT K13 parasites in which this protein was conditionally knocked
sideways to cause loss of function [27]. The same study also identified several proteins (includ-
ing K13, Eps15, UBP1 and AP-2μ) required for hemoglobin endocytosis, of which only K13
was required for rings. This conditional knock sideways system was also recently used by Yang
et al. to show reduced hemoglobin processing in ring-stage parasites with mislocalized K13
[28]. Stalling of hemoglobin import could have two positive outcomes: less availability of Fe2
+-heme to activate ART [27,28], and fewer hemoglobin-derived peptides that could trigger a
starvation response and entry into a temporary dormant state [67]. Both effects could enable
K13 mutant ring stages to survive ART exposure [27,28,68–71].
In mammalian cells, several Rab effector proteins can regulate phosphoinositide metabo-
lism. One of these effectors, a partner of Rab5 and Rab7, is the heterodimeric phosphatidylino-
sitol-3-kinase (PI3K) Vps34/Vps15 complex, which catalyzes the phosphorylation of
phosphatidylinositol to phosphatidylinositol-3-phosphate (PI3P) [72–75]. A prior report asso-
ciated ART resistance with elevated PI3P levels, mediated by an interaction between K13 and
PI3K. The rise in PI3P levels in mutant parasites was attributed to reduced binding of K13 to
PI3K, resulting in attenuated ubiquitin-mediated degradation of the kinase [34]. PI3K itself
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was not observed in our co-IP experiments. Nonetheless, there may be a link between PI3P lev-
els and the association we observed between K13 and Rab5 and Rab7, as Rab GTPase activa-
tion contributes to the stimulation of PI3K enzymatic activity, leading to localized synthesis of
PI3P and regulation of endocytic trafficking [72–75].
The co-localization we observe between the ER chaperone BiP and K13, notably the R539T
variant, supports a link between K13 and protein homeostasis and damage response pathways
(Fig 3E). IEM studies also frequently detected K13 close to the perinuclear parasite ER. These
results suggest that mutant K13 might act in part by enhancing ER-associated stress responses
to damaged proteins [31,53]. Although BiP co-immunoprecipitated with K13 in all samples
across all experiments, it was excluded from our list of putative K13-interacting partners
(Table 2 and S2 Table) due to its abundant presence in the negative control samples. Nonethe-
less, we observed several other ER proteins including PDI-14, Sec61, SEY1 and p97 in our co-
IP data, corroborating the IFA and IEM data that partially localized K13 to the ER. We note
that interactions with ER-lumenal proteins may arise after detergent-mediated cell lysis, given
that K13 lacks a known signal sequence to access the ER lumen.
Fig 5. Summary of PCC values for K13 and selected markers upon DHA or DMSO treatment. Schematic showing the
subcellular localization of markers used for IFA co-localization studies with K13. The gradient squares illustrate the
median PCC values for the spatial association between a given marker and WT or mutant K13. PCC values are shown for
DHA- or DMSO-treated parasites and were calculated immediately (0h) post treatment. The Cam3.IIR539T and Cam3.
IIWT lines were employed for all assays, with the exception of those testing the association between K13 and Rab6 that
employed the Dd2R539T Rab6-GFP and Dd2WT Rab6-GFP lines. PCC values are also presented in Figs 2–4, S5 Table and
S6 Table. A, apicoplast; DHA, dihydroartemisinin; DMSO, dimethyl sulfoxide; DV, digestive vacuole; EE, early
endosome; ER, endoplasmic reticulum; G, Golgi apparatus; LE, late endosome; M, mitochondria; MUT, mutant; N,
nucleus; PCC, Pearson correlation coefficient; R, ribosome; RE, recycling endosome; WT, wild-type.
https://doi.org/10.1371/journal.ppat.1008482.g005
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The ER is not the sole organelle responsible for sensing and combatting cellular stress.
Mitochondria likewise regulate an array of cellular functions including ATP production, intra-
cellular calcium buffering, redox homeostasis, and apoptosis [76,77]. There is increasing evi-
dence that the unfolded protein response, generally viewed as a signaling pathway to overcome
proteotoxic ER stress, also regulates mitochondrial proteostasis and function [78]. Communi-
cation between these two organelles is achieved via specialized mitochondria-associated mem-
brane contact sites (MAMs), where Ca2+ transfer, lipid synthesis and autophagosome
assembly take place. In times of stress, Ca2+ flow into the mitochondria can augment mito-
chondrial respiratory chain activity, increasing energy resources to mount an adaptive stress
response [78]. Our co-IP data revealed multiple putative K13-interacting mitochondrial pro-
teins whose functions span oxidative stress responses, the electron transport chain, and mito-
chondrial protein synthesis (Table 2 and S2 Table). Without DHA, an association between
K13 and the mitochondria was essentially nonexistent, but PCC values for K13 and Mito-
Tracker increased significantly post DHA treatment, especially for the K13 R539T mutant.
This putative association was not tested in the Birnbaum et al. study, which did not examine
whether treatment with an ART derivative would alter their set of K13-interacting candidates
[27]. We caution that our co-IP data associating K13 with mitochondrial proteins might be
adversely affected by detergent-based extraction conditions that could lead to false associations
with this organelle. Nonetheless, we observed partial colocalization of K13 with MitoTracker-
stained mitochondria upon DHA treatment, and note a recent study with Toxoplasma gondii
parasites that provided evidence of ART targeting the mitochondria, where it affected mem-
brane potential and organelle morphology [79].
The association between K13 and the mitochondria that we observed recalls earlier evi-
dence of ART accumulating in this organelle, as well as in the DV, causing mitochondrial
swelling as early as 2h post drug exposure [80]. The mode of action of ART and other endoper-
oxides has also been linked to the rapid depolarization of the mitochondrial membrane poten-
tial, with surviving cells maintaining mitochondrial polarization and activity despite
widespread cellular damage [81,82]. Mitochondrial membrane depolarization was attributed
to the formation of reactive oxygen species, most likely originating from iron-mediated bioac-
tivation of the ART endoperoxide bridge. Using a genetically-encoded, mitochondria-targeted
GFP-fusion redox probe, we found substantial oxidation following 4h or 24h of DHA treat-
ment, which greatly exceeded any oxidative effect of the cytochrome bc1 inhibitor ATQ or the
hemozoin inhibitor CQ. These results agree with earlier studies that also showed an impact of
ART derivatives on redox potential in the parasite cytosol [56,83,84]. Further studies are mer-
ited to elucidate the role of the mitochondria in both DHA action and K13-mediated resis-
tance. One possibility is that this organelle might act as an initial sensor of ART action, with
mutant K13 altering mitochondrial functionalities in ways that have downstream impacts
across an array of pathways, including reversible entry into quiescence during ART exposure
or subsequent recovery of resistant parasites. Further studies into the connection between K13
function and the mitochondria could substantially advance our understanding of parasite
physiology and its capacity to counter ART-mediated proteotoxic and oxidative stress.
Materials and methods
Production of monoclonal antibodies to K13
Antibodies were raised against K13 by injecting mice intraperitoneally with two types of
immunogens: recombinant BTB plus propeller domain (~40 kDa) or recombinant propeller
domain alone (~32 kDa) (Fig 1A). Immunogens were kindly provided by Dr. Raymond Hui
(University of Toronto). Mice were immunized five times at three-week intervals. Sera were
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collected 9–10 days after the last immunization, and titers of anti-K13 IgG were measured by
ELISA using His-tagged versions of the recombinant K13 proteins bound to Ni2+-coated
ELISA plates. Mice with the highest antibody titers were selected for anti-K13 hybridoma pop-
ulations, which were generated via polyethylene glycol (PEG)-induced fusion of the MEP-2S
fusion partner cell line with murine splenic B cells. Hybridoma cell lines were maintained in
RPMI-1640 medium supplemented with 10% FBS, L-glutamine, non-essential amino acids,
sodium pyruvate and vitamins. Stable clones were selected in the presence of hypoxanthine-
aminopterine-thymidine (HAT) medium. Hybridoma populations producing K13-specific
antibodies, as determined by ELISA, were expanded and cloned to assure the monoclonal
nature of antibodies. Clones selected via ELISA were further screened for their K13 specificity
by IFAs with the NF54WTattB-GFP-K13WT line. Clones were also tested by Western blot
against the immunogens. Purified clonal mAbs were generated from K13-positive
hybridomas.
Plasmid construction
For GFP-K13 expression studies, the K13 WT coding sequence (PlasmoDB ID
PF3D7_1343700) was amplified from genomic DNA using p3947 and p3948 (S7 Table) and
cloned into a pDC2-based expression system downstream of GFP using the BglII and XhoI
restriction sites [42]. The K13 5’ untranslated region (UTR) was amplified as a 2000 bp frag-
ment using p4376 and p4377 (S7 Table) and cloned into the ApaI and AvrII restriction sites.
We then fused the full-length K13 coding sequence to an N-terminal GFP tag and placed this
sequence under the regulatory control of the endogenous promoter. This plasmid was named
pDC-2000-GFP-K13WT-bsd-attP. For 3HA-K13 expression studies, the K13 C580Y coding
sequence was used instead, and the P. berghei ef1α promotor (PBANKA_1133400) was used as
a 5’ regulatory element. The N-terminal GFP tag was replaced with an N-terminal 3HA tag at
the AvrII and BglII sites. The 3HA sequence was synthetically engineered with the correspond-
ing restriction sites in a pUC57-Amp vector (Genewiz). The resulting plasmid was named
pDC2-EF1α-3HA-K13C580Y-bsd-attP. In both plasmids hsp86 3’UTR was used as a terminator
sequence for the K13 expression cassette and a bsd (blasticidin S-deaminase) cassette was used
as a selectable marker [85].
To episomally express the GFP-Rab6 transgene we amplified the Rab6 coding sequence
(PlasmoDB ID PF3D7_1144900) from genomic DNA using poML214 and poML204 (S7
Table) and cloned this fragment into the pDC2-based expression system downstream of GFP
using the BglII and XhoI restriction sites [42]. Using p1144 and p1263 (S7 Table), about 1.3 kb
of the Sec12 (PlasmoDB ID PF3D7_1116400) 5’ UTR was amplified as the promoter and
cloned into the ApaI and AvrII restriction sites. The hsp86 3’UTR served as a terminator
sequence for the expression cassette and human dhfr (dihydrofolate reductase) was used as the
selectable marker. The plasmid was named pDC2-sec12-GFP-PfRab6-hDHFR.
Parasite culture and transfection
P. falciparum asexual blood-stage parasites were cultured in human erythrocytes (3% hemato-
crit) and RPMI-1640 medium supplemented with 2 mM L-glutamine, 50 mg/L hypoxanthine,
25 mM HEPES, 0.225% NaHCO3, 10 mg/L gentamycin and 0.5% w/v Albumax II (Invitrogen).
Parasites were maintained at 37˚C in 5% O2, 5% CO2, and 90% N2. Cultures were stained with
Giemsa, and monitored by blood smears fixed in methanol and viewed by light microscopy.
NF54WTattB-GFP-K13WT and NF54WTattB-3HA-K13C580Y parasite lines were generated by
attB×attP crossover-mediated integration of either the pDC-2000-GFP-K13WT-bsd-attP or the
pDC2-EF1α-3HA-K13C580Y-bsd-attP plasmid into the cg6 locus in the NF54WTattB parasite
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line [86] (S1 Fig). Crossover events were mediated by Bxb1 serine integrase, which was
expressed on the pINT plasmid that contains the neomycin selectable marker and that was co-
electroporated with either pDC2 plasmid. The NF54C580YattB-GFP-K13C580Y line was gener-
ated using a K13-specific CRISPR/Cas9 system that enabled us to edit both the endogenous
and transgene copies of K13 in the NF54WTattB-GFP-K13WT line (Stokes et al., manuscript in
preparation). This system was also used to generate the NF54WTattB-3HA-K13WT line by
CRISPR/Cas9-editing the K13 C580Y transgene locus in the NF54WTattB-3HA-K13C580Y line.
Dd2WT or Dd2R539T GFP-Rab6 parasite lines were generated via transfection of the
pDC2-sec12-GFP-PfRab6-hDHFR plasmid and episomal selection using 2.5 nM WR99210
(Jacobus Pharmaceuticals, Princeton, NJ).
Transfections were performed by electroporating ring-stage parasites at 5–10% parasitemia
with 50 μg of purified circular plasmid DNA in resuspended in Cytomix [87]. Transfected par-
asites were maintained under 2.5 μg/mL blasticidin (Thermo Fisher) or 2.5 nM WR99210
drug pressure to select for maintenance of the pDC2-based bsd or hdhfr plasmids respectively,
and 125 μg/mL G418 (Fisher) to select for pINT. Blasticidin or WR99210 pressure was main-
tained until parasites were detected microscopically, whereas G148 pressure was applied for
only the first six days post electroporation. Parasite cultures were monitored by microscopy
for up to six weeks post electroporation. To test for successful integration of the attP plasmids,
trophozoite-infected erythrocytes were harvested and saponin-lysed, and genomic DNA was
isolated using QIAamp DNA Blood Mini kit (Qiagen). PCR-based screening for integration is
shown in S1 Fig, with primers listed in S7 Table. Integrated parasites were cloned via limiting
dilution, and flow cytometry was used to screen for positive wells after 17–20 days. Parasites
were stained with 1×SYBR Green (Thermo Fisher) and 100 nM MitoTracker Deep Red (Invi-
trogen) and detected using an Accuri C6 flow cytometer (Becton Dickinson; [88]). Expression
of the tagged proteins in the clonal lines was verified via Western blot and IFA with anti-GFP
or anti-HA primary antibodies, as described below.
Western blotting
Parasite lysates for Western blotting were prepared on ice. Infected erythrocytes were washed
twice in cold 1× phosphate-buffered saline (PBS), and parasites were isolated from RBCs by
treatment with 0.05% saponin in PBS. Released parasites were resuspended in cold lysis buffer
(0.15 M NH4Cl, 1 mM NaHCO3, 0.1 mM Na2EDTA, pH 7.4) supplemented with 1× protease
inhibitors (Halt Protease Inhibitors Cocktail, Thermo Fisher) and incubated on ice for 30 min.
RBC membranes were lysed with 0.1% Triton X100 in PBS supplemented with protease inhibi-
tors for 10 min, with frequent vortexing and trituration. Samples were centrifuged at 14,000
rpm for 10 min at 4˚C to pellet cellular debris. Supernatants were collected and protein con-
centrations were determined using the DC protein assay kit (Bio-Rad). Laemmli Sample Buffer
(Bio-Rad) was added to lysates and samples were denatured at 90˚C for 10 min. Proteins were
electrophoresed on 10% Bis-Tris gels (Bio-Rad) and transferred onto a nitrocellulose mem-
brane. Western blots were probed with primary antibodies to K13 or to GFP or 3×HA epitope
tags (1:1,000 dilutions for all) and incubated with HRP-conjugated secondary antibodies
(1:10,000 dilution). Western blots were revealed using ECL Western Blotting Substrate
(Thermo Fisher). For primary antibodies, we used Living Colors full-length anti-GFP poly-
clonal antiserum (Takara (Clontech)), anti-HA antibodies produced in rabbit (Sigma), rabbit
anti-ERD2 antibodies (BEI Resources) and mouse anti-β actin antibodies (clone AC-15, Invi-
trogen). As secondary antibodies, we used goat anti-rabbit IgG H&L (HRP) (Abcam) or goat
anti-mouse IgG H&L (HRP) (Abcam).
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Immunofluorescence assays
Parasites were synchronized with 5% D-sorbitol treatment and harvested either every 12h
throughout the 48h life cycle, or were pulsed with DHA (6h, 700 nM) or Brefeldin A (1h, 5 μg/
mL) (Sigma Aldrich) and then harvested post treatment. DMSO was used as vehicle control in
the case of DHA treatments and EtOH in the case of BFA (S3 Fig). DHA-treated parasites
were harvested either immediately (0h) post treatment, or 3, 12, or 24h post treatment. BFA-
treated parasites were harvested 1h post treatment.
IFAs were performed with cells in suspension. Harvested cells were washed twice in 1×PBS
and fixed in 4% v/v formaldehyde (Fisher) supplemented with 0.0075% v/v glutaraldehyde
(Sigma) in PBS for 30 min at room temperature. Cell membranes were permeabilized in 0.1%
Triton X-100 in PBS for 30 min. Autofluorescence was quenched using 0.1 M glycine in PBS
for 15 min. Blocking was performed with 3% w/v bovine serum albumin (BSA) for at least 1h
at room temperature, or overnight at 4˚C. Cells were incubated with primary antibodies for 90
min at room temperature or overnight at 4˚C, with dilutions ranging from 1:50–1:200, fol-
lowed by incubation with a species-specific fluorophore-conjugated secondary antibody
(Alexa Fluor 488-, 594- or 647-conjugated goat anti-mouse, -rabbit or -rat antibody, Thermo
Fisher) diluted 1:2,000 to 1:4,000 in 3% BSA and 0.1% Tween in PBS. As primary antibodies,
we used rabbit anti-BiP (kindly provided by Min Zhang), rabbit anti-ERD2 (BEI Resources),
rabbit anti-Rab5A, -Rab5C, or -Rab11A, rat anti-Rab5B or -Rab7 (kindly provided by Dr. Gor-
don Langsley), rabbit anti-TRiC (kindly provided by Zbynek Bozdech), rabbit anti-HAD1
(kindly provided by Dr. Audrey Odom John), rabbit anti-GFP ((Takara (Clontech)), or rabbit
anti-HA (Sigma). MitoTracker Red CMXRos (Thermo Fisher) was used to stain
mitochondria.
Thin blood smears of stained RBCs were prepared on microscope slides and mounted with
cover slips using Prolong Diamond Antifade Mountant with DAPI (Thermo Fisher). Slides
were imaged using a Nikon Eclipse Ti-E wide-field microscope equipped with a sCMOS cam-
era (Andor) and a Plan-apochromate oil immersion objective with 100× magnification (1.4
numerical aperture). A minimum of 15 Z-stacks (0.2 μm step size) were taken for each parasit-
ized RBC. NIS-Elements imaging software (Version 5.02, Nikon) was used to control the
microscope and camera as well as to deconvolve images and perform 3D reconstructions.
Deconvolution was performed using 25 iterations of the Richardson-Lucy algorithm for each
image. Quantitative co-localization analysis of the deconvolved Z-stacks was performed using
the GA3 pipeline (General analysis Pipeline 3; NIS-Elements software; developed in collabora-
tion with Nikon). ImageJ (Fiji version 2.0.0-rc-68/1.52h) was used to crop images, adjust
brightness and intensity, overlay channels and prepare montages. For super resolution imag-
ing, we used either a Nikon N-SIM S Super Resolution Microscope or a W1-Yokogawa Spin-
ning Disk Confocal with a CSU-W1 SoRa Unit. For 3D image analysis, we used Imaris x64
version 6.7 (Bitplane).
Immunoelectron microscopy
Trophozoites were magnetically sorted from uninfected RBCs and ring-stage parasites via
MACS LD separation columns (Miltenyi Biotech). Parasites were collected by centrifugation
and fixed for 1h at 4˚C in 4% paraformaldehyde (Polysciences Inc.) in 100 mM PIPES with 0.5
mM MgCl2 (pH 7.2). Samples were embedded in 10% gelatin and infiltrated overnight with
2.3 M sucrose and 20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4˚C. Samples were trimmed,
frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT7 cryo-ultramicrotome
(Leica Microsystems Inc.). 50 nm sections were blocked with 5% fetal bovine serum and 5%
normal goat serum for 30 min, and subsequently incubated with primary antibodies for 1h at
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room temperature (anti-PDI (1D3) mouse diluted 1:50, anti-GFP rabbit 1:200, anti-GFP
mouse 1:200, anti-HA rabbit 1:50–1:250, anti-BiP rabbit 1:100, anti-Rab5A rabbit 1:50, anti-
Rab5B rat 1:50, or anti-Rab7 rabbit 1:50; Rab11A antibodies could not be used as they failed to
give signals under our conditions). Species-specific colloidal-gold conjugated secondary anti-
bodies (6 nm, 12 nm or 18 nm particles; Jackson ImmunoResearch) were added at a 1:30 dilu-
tion for 1h at room temperature. Sections were stained with 0.3% uranyl acetate and 2%
methyl cellulose, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL
USA Inc.) equipped with an AMT 8-megapixel digital camera and AMT Image Capture
Engine V602 software (Advanced Microscopy Techniques). All labeling experiments were
conducted in parallel with controls omitting the primary antibodies. These controls were con-
sistently negative at the concentration of colloidal gold-conjugated secondary antibodies used
in these studies.
Co-immunoprecipitation (Co-IP) studies
Co-IP studies were performed using the Pierce Direct IP kit (Thermo Fisher). Briefly, parasites
were extracted from infected erythrocytes as described above, resuspended in Pierce IP Lysis
Buffer supplemented with 1× Halt Protease and Phosphatase Inhibitor Cocktail and 25U
Pierce Universal Nuclease, and lysed on ice for 10 minutes with frequent vortexing. Samples
were centrifuged at 14,000 rpm for 10 min at 4˚C to pellet cellular debris. Supernatants were
collected and protein concentrations were determined using the DC protein assay kit (Bio-
Rad). IPs were performed used 500 μg of lysate per test sample. A mix of K13 E3 and D9 mAbs
(2.5 μg each per test sample) was used for IP. Antibody coupling to IP columns, IP, and elution
steps were performed according to Pierce instructions. Eluates were analyzed by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) to identify immunoprecipitated
proteins.
Ring-stage survival assays (RSA0-3h)
RSA0-3h assays were carried out as previously described [17], with minor modifications. In
brief, parasite cultures were synchronized 1–2 times using 5% sorbitol (Fisher). Synchronous
schizonts were incubated in RPMI-1640 containing 15 units/mL sodium heparin (Fisher) for
15 min at 37˚C to disrupt agglutinated erythrocytes, concentrated over a gradient of 75% Per-
coll (Fisher), washed once in RPMI-1640, and incubated for 3h with fresh RBCs to allow time
for merozoite invasion. Cultures were subjected again to sorbitol treatment to eliminate
remaining schizonts. 0–3h post-invasion rings were adjusted to 1% parasitemia and 2% hemat-
ocrit and exposed to 700 nM DHA or 0.1% DMSO (vehicle control) for 6h. Alternatively, early
rings were exposed to 4h to 60 nM, 100 nM or 1200 nM ATQ, or combinations thereof. These
concentrations were selected based on separate studies from our lab showing synergy between
DHA and ATQ against Cam3.IIR539T parasites at these concentrations. Cells were washed to
remove drug and returned to standard culture conditions for an additional 66h. Parasite
growth in each well was assessed using flow cytometry. Parasites were stained with 1x SYBR
Green and 100 nM MitoTracker Deep Red (Thermo Fisher), and parasitemias were measured
on a BD Accuri C6 Plus Flow Cytometer with a HyperCyt attachment sampling 60,000–
100,000 events per well. After 72h, cultures generally expanded to 3–5% parasitemia in
DMSO-treated controls. Percent survival of DHA-treated parasites was calculated relative to
the corresponding DMSO-treated control.
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Confocal live-cell imaging
P. falciparum 3D7 parasites were episomally transfected with pARL1a-Mito-hGrx1-roGFP2,
which expresses an oxidation-reduction sensitive GFP fused at its N-terminus to human glu-
taredoxin 1 (Table 1). This fusion protein is targeted to the mitochondria using the citrate
synthase leader sequence, as described previously [56]. Transfected parasites were used to test
the oxidizing effects of antimalarials on the parasite mitochondria. For 30 min exposure exper-
iments we incubated trophozoites with 100 μM DHA, ATQ, or CQ. For mid-term 4h incuba-
tions we exposed young trophozoites to 5 μM DHA, ATQ, or CQ. Long-time 24h exposures
began with young ring-stage parasites, which were exposed to 50 nM DHA, ATQ, or CQ.
Following drug exposure, parasites were blocked with 2 mM N-ethylmaleimide (NEM) for
15 min. Trophozoite-stage parasites were magnetically enriched and eluted in pre-warmed
Ringer’s solution and seeded on poly-lysine coated μ-slides VI (Ibidi, Martinsried, Germany).
Live-cell imaging was performed on a Leica confocal system TCS SP5 inverted microscope
equipped with an HCX PL APO 63.0 x 1.30 GLYC 37˚C UV objective and a 37˚C temperature
chamber, as previously described [83]. Smart gain was set to 222.0 V, smart offset was 12.3%
and argon laser power was set to 20%. To calibrate the microscope, we used parasites whose
redox state was either fully reduced with 10 mM DTT or fully oxidized with 1 mM DIA. Data
were analyzed using Leica LAS AF software. The degree of mitochondrial oxidation (OxD)





ðRox  RÞ þ ðR  RredÞ
R represents the ratio of the fluorescence intensity measured at 405 nm and 488 nm
(R ¼ 405 nm
488 nm); Rred and Rox are the ratios of the fluorescence intensity of fully reduced or fully
oxidized parasites, respectively; I488ox is the fluorescence intensity at 488 nm for fully oxidized
parasites; and I488red is the fluorescence intensity at 488 nm for fully reduced parasites [89].
Graphs were plotted using GraphPad Prism version 8.
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Supporting information
S1 Fig. Generation of NF54WTattB-GFP-K13WT and NF54WTattB-3HA-K13C580Y parasites.
(A) Schematic of GFP-K13WT or 3HA-K13C580Y gene sequence integration into NF54WT para-
sites containing an attB site in the cg6 locus [90]. The two plasmids used for co-transfection
are represented at the top. pINT codes for the integrase expression unit (Int) and a neomycin
resistance cassette (Neo). pDC-2000-GFP-K13WT-bsd-attP contains an N-terminal
GFP-K13WT fusion protein under the control of the endogenous K13 promoter (k13 5’UTR),
and a blasticidin S-deaminase (BSD) resistance cassette adjacent to the attP coding site.
pDC-EF1α-3HA-K13C580Y-bsd-attP contains an N-terminal 3HA-K13C580Y fusion protein
under the control of the pbef1α promoter, and a BSD resistance cassette. Integrase-mediated
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recombination between the attP and attB sequences resulted in integration of the full-length
pDC2-based plasmids, yielding the NF54WTattB-GFP-K13WT and NF54WTattB-
3HA-K13C580Y transgenic parasite lines. (B) Primer combinations and expected amplicon
sizes used for PCR-based integration screening. Primer positions are indicated with arrows in
(A) and primer sequences are listed in S7 Table. (C) PCR analysis of the two transgenic lines
using the primer sets listed in (B). (D) Western blots of parasite extracts probed with the anti-
K13 mAb E9. This antibody recognizes full-length K13 (~85 kDa) and lower molecular weight
bands. We attribute the latter to N-terminal degradation products, based on our observation
of very high co-localization values between K13 mAbs and antibodies to either GFP or 3HA in
K13 transgenic lines, as well as the finding that antibodies to GFP or 3HA both recognized
fusion proteins consistent with a K13 mass of ~85 kDa (as seen in Fig 1A). (E) Representative
Western blot analysis of synchronized 0-6h ring-stage parasites from the K13- isogenic lines
Cam3.IIWT, Cam3.IIC580Y and Cam3.IIR539T, probed with K13 mAb E9 and mouse monoclo-
nal anti-β actin. The right panel shows ImageJ-generated quantification of K13 C580Y or K13
R539T protein compared to K13 WT protein, with all proteins normalized to the β-actin load-
ing control. These data yielded relative mean ± SEM expression levels of 76 ± 3% and 66 ± 4%
for Cam3.IIC580Y and Cam3.IIR539T relative to the WT control, corresponding to mean K13
protein percent reductions of 24% and 34% for these two mutant proteins respectively.
(PDF)
S2 Fig. Additional super resolution imaging of (A) Cam3.IIWT and (B) Cam3.IIR539T tropho-
zoites, labeled with antibodies to K13 and the cytosolic marker HAD1. Images were acquired
using a W1-Yokogawa Spinning Disk Confocal microscope equipped with a CSU-W1 SoRa
Unit. (C) Quantification of antibody-labeled K13 foci in Cam3.IIWT and Cam3.IIR539T tropho-
zoites, yielding an estimated 48% reduction in K13 R539T protein compared to the K13 WT
levels.
(PDF)
S3 Fig. Schematic of the protocol used for synchronizing and treating parasites for immu-
nofluorescence co-localization studies. DHA, dihydroartemisinin; DMSO, dimethyl sulfox-
ide; MACS, magnetic-activated cell sorting.
(PDF)
S4 Fig. K13 partially co-localizes with Rab GTPases and Sec24a. (A) Representative IFA
images showing DMSO-treated Cam3.IIWT ring-stage parasites co-stained with anti-K13 mAb
E3 and antibodies to Rab5A, Rab5B, or Rab5C (top, middle and bottom panels, respectively).
Samples were collected immediately post treatment. Scale bars: 2 μm. (B) Fluorescence micros-
copy/DIC overlay and 3D volume reconstruction showing the spatial association between K13
and Rab5A in Cam3.IIWT parasites sampled 12h post DMSO mock treatment. Scale bars are
indicated. (C) Representative IFA images showing GFP-Rab6-expressing parasites co-stained
with K13 mAb E3. Assays were conducted with Dd2WT (top) and Dd2R539T (bottom) ring-
stage parasites episomally expressing GFP-Rab6, and samples were collected immediately post
DMSO treatment. Scale bars: 2 μm. (D) Representative IFA images showing DMSO-treated
Cam3.IIWT ring-stage parasites co-stained with anti-K13 mAb E3 and antibodies to Rab7 (top)
or Rab11A (bottom). Samples were collected immediately post treatment. Scale bars: 2 μm. (E)
Fluorescence microscopy/DIC overlay and 3D volume reconstruction showing the spatial
association between K13 and Rab11A in Cam3.IIWT parasites sampled 12h post DMSO treat-
ment. (F) Representative IEM images of NF54WTattB-GFP-K13WT (left) or NF54WTattB-
3HA-K13C580Y (right) trophozoites stained with anti-GFP or anti-HA antibodies, and either
co-stained with antibodies to Rab5A (top), or Rab5B (bottom left), or triply labeled with anti-
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Rab5B and anti-PDI antibodies (bottom right). Arrows highlight locations of interest. ER,
endoplasmic reticulum; Hz, Hemozoin; M, mitochondria; N, nucleus. Scale bars: 100 nm. (G)
PCC values for the spatial association between K13 and Sec24a immediately post DHA pulse
(6h, 700 nM) or DMSO mock treatment. Assays were conducted on Dd2WT ring-stage para-
sites episomally expressing Sec24a-GFP. Parasites were stained with anti-GFP and the K13
mAb E3. Right panels show representative 3D volume reconstructions of DMSO-treated or
DHA-pulsed Sec24a-GFP expressing parasites. PCC values were calculated and statistics per-
formed as in Fig 2. Scale bars: 1 μm. (H) Representative IFA images showing Dd2WT Sec24a-
GFP-expressing parasites co-stained with K13 mAb E3 and anti-GFP. Samples were collected
immediately post DMSO mock treatment. Scale bars: 2 μm. Several DIC images as well as
montages showing the individual color channels complement the 3D volume view of parasites
shown in Fig 2.
(PDF)
S5 Fig. K13 exhibits extensive co-localization with the parasite ER. (A) Fluorescence
microscopy/DIC overlay and 3D volume reconstructions of deconvolved Z-stacks showing the
spatial association between K13 and BiP in Cam3.IIWT (top) and Cam3.IIR539T (bottom) tro-
phozoites (untreated). Parasites were co-stained with the K13 E3 mAb and anti-BiP antibodies.
Scale bars: 2 μm. (B) Representative IEM images of NF54WTattB-GFP-K13WT trophozoites co-
stained with anti-GFP and anti-BiP antibodies. Arrows highlight locations of interest. Hz,
hemozoin; N, nucleus. Scale bars: 100 nm. (C) PCC values for the spatial association of K13
and BiP in Cam3.IIR539T and Cam3.IIWT ring-stage parasites treated and analyzed as in Fig
3B–3E. (D) Representative IFA images showing Cam3.IIWT ring-stage parasites co-stained
with anti-K13 E3 and either anti-BiP (left) or anti-ERD2 (right) antibodies. Parasites were
sampled immediately post DHA pulse (6h, 700 nM) or DMSO mock treatment. Scale bars:
2 μm.
(PDF)
S6 Fig. K13 localizes to mitochondria-associated membranes. (A) PCC values for the associ-
ation of K13 with parasite mitochondria in NF54WTattB-GFP-K13WT ring-stage parasites co-
stained with MitoTracker Deep Red and anti-GFP. Samples were collected either 0h or 12h
post DHA pulse (6h, 700 nM). DMSO was used as a vehicle control. PCC values were calcu-
lated and statistics performed as in Fig 2. (B-E) PCC values for the association of (B) ERD2,
(C) TRiC, (D) Rab5A, or (E) Rab11A with parasite mitochondria in Cam3.IIR539T and Cam3.
IIWT ring-stage parasites. Samples were collected 0h post DHA pulse (6h, 700nM). Parasites
were co-stained with MitoTracker Deep Red and marker-specific antibodies. (F) Additional
representative 3D volume reconstructions of untreated late (left) Cam3.IIR539T and (right)
Cam3.IIWT trophozoites triply stained with MitoTracker, anti-BIP (ER, green) and anti-K13
E3 (purple). White dotted outlines indicate spatial overlap between the three labels. Scale bars:
1 μm. (G) Percent survival for Cam3.IIR539T and Cam3.IIWT 0–3 hpi rings treated for 4h with
DHA and/or ATQ at the concentrations indicated (in nM). Data show mean ± SEM for three
independent experiments performed in duplicate.
(PDF)
S1 Video. 3D rotations of a Cam3.IIWT late trophozoite labeled with anti-K13 (green) and
anti-HAD1 (red) antibodies.
(MP4)
S1 Table. Co-immunoprecipitation experimental details.
(PDF)
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S2 Table. Putative K13-interacting protein partners identified by co-immunoprecipitation
and LC/MS-MS (relaxed criteria).
(PDF)
S3 Table. PANTHER overrepresentation test for biological processes.
(PDF)
S4 Table. PANTHER overrepresentation test for cellular components.
(PDF)
S5 Table. Pearson correlation coefficient values for IFA studies.
(PDF)
S6 Table. Pearson correlation coefficient values for MitoTracker Deep Red imaging stud-
ies.
(PDF)
S7 Table. Oligonucleotides used in this study.
(PDF)
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